CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Solvonis Therapeutics PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Solvonis Therapeutics PLC
Eccleston Yards, 25 Eccleston Place
LONDON, SW1W 9NF  United Kingdom Ticker: SVNSSVNS
Business Summary
Solvonis Therapeutics PLC is a clinical-stage biotechnology company developing treatments for addiction and mental health disorders. The Company is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need. It is focused on Alcohol Use Disorder (AUD), which affects over 40 million people across the United States, United Kingdom, and EU4 markets, and Post-Traumatic Stress Disorder (PTSD), impacting more than 13 million adults in the United States and approximately 20 million across those same regions. AUD is characterized by compulsive, harmful drinking, and is associated with significant health risks, including chronic diseases, mental health conditions and accidents, injuries and violence. PTSD is a complex and debilitating mental health condition that develops in some people who have experienced traumatic events, for example violence, an accident, war or a natural disaster.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024Yes----

Industries
SIC Code Description
2821 Plastics materials, synthetic resins, and nonvulcanizable elastomers
7389 Business services, not elsewhere classified
2824 Manmade organic fibers, except cellulosic
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Dennis J.Purcell 9/26/2024 9/26/2024
Chief Executive Officer, Executive Director AnthonyTennyson 5/2/2024 5/2/2024
Chief Marketing Officer PavelKobzev 7/15/2024 5/25/2019
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Awakn Life Sciences Corp 301-217 Queen St West TORONTO ON Canada

Business Names
Business Name
Awakn Life Sciences Corp
GPL
SVNS

General Information
Outstanding Shares: 5,908,770,690 (As of 5/27/2025)
Stock Exchange: LON


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, June 27, 2025